Pfizer Inc. (NYSE:PFE) Shares Sold by Winch Advisory Services LLC

Winch Advisory Services LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,212 shares of the biopharmaceutical company’s stock after selling 1,469 shares during the quarter. Winch Advisory Services LLC’s holdings in Pfizer were worth $469,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer during the second quarter worth $29,000. Quarry LP acquired a new stake in shares of Pfizer during the second quarter worth $31,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the second quarter worth $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $28.93 on Tuesday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a market cap of $163.93 billion, a PE ratio of -482.17, a P/E/G ratio of 1.02 and a beta of 0.67. The stock has a 50 day simple moving average of $29.07 and a 200-day simple moving average of $28.47. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the company earned $0.67 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.81%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on PFE shares. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Wells Fargo & Company lifted their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.